healthcare

healthcare Articles

Altimmune made some progress with its COVID-19 treatment on Monday after it announced some new funding for its trials.
More investors now consider waste removal and cleaning company BioHiTech Global to be among those on the growing list of COVID-19 stocks. Thus, its shares more than doubled to start out the week.
Gilead has priced its COVID-19 drug candidate at $2,340 for a five-day treatment in the United States and some other developed countries. The company set the price for a single vial of remdesivir at...
Intercept Pharmaceuticals stock was crushed early on Monday after the firm received an update from the FDA in regards to its treatment of fibrosis due to nonalcoholoic steatohepatitis.
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The FDA has notified Fulcrum Therapeutics that it is allowed to proceed with initiating its Phase 3 trial of losmapimod in higher risk hospitalized adults with COVID-19.
GW Pharmaceuticals took a big step forward for the development of its cannabidiol product in the United Kingdom.
A labeling requirement in California warning consumers of the risks of products derived from cannabis could have a chilling effect on the state's legal growers and retailers.
Inovio Pharmaceuticals has announced that it received $71 million in funding from the U.S. Department of Defense to support the production of its delivery device for the COVID-19 vaccine.
Sanofi and Translate Bio are making waves in the fight against the novel coronavirus as the two have agreed to expand their existing 2018 collaboration and license agreement
Sintx Technologies shares nearly tripled after the company announced a big win against the coronavirus in a controlled laboratory study.
Evoke Pharma says the FDA has approved its New Drug Application for Gimoti nasal spray for symptom relief in adults with acute and recurrent diabetic gastroparesis.
1Life Healthcare is known for its One Medical service, which is effectively a membership-based primary care model. One analyst called it "a next-generation primary care provider."
The announcement that AnPac Bio-Medical Science has entered into a three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management in China lit a fire under the...
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.